Ascendis Pharma A/S
ASND212.110USD
-1.130-0.53%
Close 12/16, 16:00（ET）Quotes delayed by 15 min
13.09BMarket Cap
LossP/E TTM
More Details of Ascendis Pharma A/S Company
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Ascendis Pharma A/S Info
Ticker SymbolASND
Company nameAscendis Pharma A/S
IPO dateJan 28, 2015
CEOMoller Mikkelsen (Jan)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endJan 28
AddressTuborg Boulevard 12
CityHELLERUP
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryDenmark
Postal code2900
Phone4570222244
Websitehttps://ascendispharma.dk/
Ticker SymbolASND
IPO dateJan 28, 2015
CEOMoller Mikkelsen (Jan)
Company Executives of Ascendis Pharma A/S
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+198.45%
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
1.86K
+100.43%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
1.59K
+78.59%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
1.09K
+178.01%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.09K
+178.01%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
364.00
--
Mr. Mads Bodenhoff
Mr. Mads Bodenhoff
Senior Vice President, Head of Finance and Principal Accounting Officer
Senior Vice President, Head of Finance and Principal Accounting Officer
193.00
--
Mr. Donovan (Jay) Wu
Mr. Donovan (Jay) Wu
Executive Vice President, U.S. President
Executive Vice President, U.S. President
--
--
Dr. Aimee Shu,, M.D.
Dr. Aimee Shu,, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+198.45%
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
1.86K
+100.43%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
1.59K
+78.59%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
1.09K
+178.01%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.09K
+178.01%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
364.00
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Commercial sale of products
153.66M
97.23%
Rendering of services
3.57M
2.26%
License
812.00K
0.51%
By RegionUSD
Name
Revenue
Proportion
North America
108.45M
68.62%
Europe
27.89M
17.65%
Rest of world
21.70M
13.73%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Commercial sale of products
153.66M
97.23%
Rendering of services
3.57M
2.26%
License
812.00K
0.51%
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
16.66%
Westfield Capital Management Company, L.P.
8.53%
Avoro Capital Advisors LLC
8.28%
Janus Henderson Investors
7.01%
Fidelity Management & Research Company LLC
6.68%
Other
52.84%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
16.66%
Westfield Capital Management Company, L.P.
8.53%
Avoro Capital Advisors LLC
8.28%
Janus Henderson Investors
7.01%
Fidelity Management & Research Company LLC
6.68%
Other
52.84%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
43.51%
Investment Advisor
36.00%
Venture Capital
16.92%
Hedge Fund
4.61%
Research Firm
2.38%
Private Equity
2.29%
Individual Investor
0.76%
Pension Fund
0.36%
Bank and Trust
0.01%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
523
68.62M
116.45%
+3.30K
2025Q3
540
68.73M
112.39%
+4.25M
2025Q2
515
64.43M
118.51%
-2.60M
2025Q1
495
67.05M
117.13%
-3.67M
2024Q4
471
65.26M
121.58%
+1.14M
2024Q3
461
64.02M
116.74%
+1.57M
2024Q2
446
62.31M
123.50%
-4.72K
2024Q1
440
62.32M
122.74%
-9.15M
2023Q4
415
61.74M
123.84%
-59.49K
2023Q3
401
61.90M
129.48%
-512.07K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
10.28M
16.88%
--
--
Jun 30, 2025
Westfield Capital Management Company, L.P.
5.45M
8.95%
-27.86K
-0.51%
Jun 30, 2025
Avoro Capital Advisors LLC
4.98M
8.18%
-238.00K
-4.56%
Jun 30, 2025
Janus Henderson Investors
4.43M
7.27%
-59.16K
-1.32%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.18M
6.86%
-125.41K
-2.91%
Jun 30, 2025
Artisan Partners Limited Partnership
3.99M
6.55%
-266.20K
-6.25%
Jun 30, 2025
Capital International Investors
3.05M
5%
+172.14K
+5.99%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
3.58M
5.88%
+529.72K
+17.35%
Jun 30, 2025
MFS Investment Management
1.90M
3.11%
+23.62K
+1.26%
Jun 30, 2025
Wellington Management Company, LLP
918.10K
1.51%
+330.33K
+56.20%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Harbor Health Care ETF
17.71%
American Century Focused Dynamic Growth ETF
2.8%
AdvisorShares Dorsey Wright ADR ETF
2.62%
Virtus LifeSci Biotech Products ETF
1.89%
Tema Heart & Health ETF
1.45%
ProShares Ultra Nasdaq Biotechnology
1.2%
Invesco Nasdaq Biotechnology ETF
1.19%
First Trust Innovation Leaders ETF
1.18%
Putnam Sustainable Future ETF
1.11%
Main Thematic Innovation ETF
1.07%
View more
Harbor Health Care ETF
Proportion17.71%
American Century Focused Dynamic Growth ETF
Proportion2.8%
AdvisorShares Dorsey Wright ADR ETF
Proportion2.62%
Virtus LifeSci Biotech Products ETF
Proportion1.89%
Tema Heart & Health ETF
Proportion1.45%
ProShares Ultra Nasdaq Biotechnology
Proportion1.2%
Invesco Nasdaq Biotechnology ETF
Proportion1.19%
First Trust Innovation Leaders ETF
Proportion1.18%
Putnam Sustainable Future ETF
Proportion1.11%
Main Thematic Innovation ETF
Proportion1.07%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Ascendis Pharma A/S?
The top five shareholders of Ascendis Pharma A/S are:
RA Capital Management, LP holds 10.28M shares, accounting for 16.88% of the total shares.
Westfield Capital Management Company, L.P. holds 5.45M shares, accounting for 8.95% of the total shares.
Avoro Capital Advisors LLC holds 4.98M shares, accounting for 8.18% of the total shares.
Janus Henderson Investors holds 4.43M shares, accounting for 7.27% of the total shares.
Fidelity Management & Research Company LLC holds 4.18M shares, accounting for 6.86% of the total shares.
RA Capital Management, LP holds 10.28M shares, accounting for 16.88% of the total shares.
Westfield Capital Management Company, L.P. holds 5.45M shares, accounting for 8.95% of the total shares.
Avoro Capital Advisors LLC holds 4.98M shares, accounting for 8.18% of the total shares.
Janus Henderson Investors holds 4.43M shares, accounting for 7.27% of the total shares.
Fidelity Management & Research Company LLC holds 4.18M shares, accounting for 6.86% of the total shares.
What are the top three shareholder types of Ascendis Pharma A/S?
The top three shareholder types of Ascendis Pharma A/S are:
RA Capital Management, LP
Westfield Capital Management Company, L.P.
Avoro Capital Advisors LLC
RA Capital Management, LP
Westfield Capital Management Company, L.P.
Avoro Capital Advisors LLC
How many institutions hold shares of Ascendis Pharma A/S (ASND)?
As of 2025Q4, 523 institutions hold shares of Ascendis Pharma A/S, with a combined market value of approximately 68.62M, accounting for 116.45% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 4.06%.
What is the biggest source of revenue for Ascendis Pharma A/S?
In FY2025Q2, the Commercial sale of products business generated the highest revenue for Ascendis Pharma A/S, amounting to 153.66M and accounting for 97.23% of total revenue.
